A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Aggrastat
Synonyms :
Class :
Antiplatelet agents; Glycoprotein receptor antagonists
Brand Name :
Aggrastat
Synonyms :
Class :
Antiplatelet agents; Glycoprotein receptor antagonists
Dosage forms & Strengths:Â
Adult:Â
Premixed IV infusion:Â
5 mg/100 mlÂ
12.5 mg/250 mlÂ
IV solution vials:Â
5 mg/100 mlÂ
3.75 mg/15 mlÂ
25
mcg/kg
Solution
Intravenous (IV)
5
minutes
may have an increased anticoagulant effect when combined with Enoxaparin
may have an increased anticoagulant effect when combined with Heparin
may enhance the photosensitizing effect of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
berotralstat: they may enhance the serum concentration of glycoprotein IIa Inhibitors
colchicine: they may enhance the serum concentration of glycoprotein IIb Inhibitors
digoxin: they may enhance the serum concentration of glycoprotein IIa Inhibitors
lefamulin: they may enhance the serum concentration of glycoprotein IIb Inhibitors
relugolix: they may enhance the serum concentration of glycoprotein IIa Inhibitors
rimegepant: they may enhance the serum concentration of glycoprotein Inhibitors
sirolimus: they may enhance the serum concentration of glycoprotein IIa Inhibitors
ubrogepant: they may enhance the serum concentration of glycoprotein inhibitors
venetoclax: they may enhance the serum concentration of glycoprotein Inhibitors
alfuzosin: they may enhance the serum concentration of glycoprotein IIB Inhibitors
amiodarone: they may enhance the serum concentration of glycoprotein IIa Inhibitors
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
when both the drugs are combined, there might be an increase in the anticoagulant effect
may enhances the effects of the other by pharmacodynamic synergism
Omega-3 Fatty Acids: they may increase the antiplatelet effect of antiplatelet agents
tenoxicam: they may increase the anticoagulant effect of Antiplatelet agents
probenecid: they may increase the anticoagulant effect of Antiplatelet agents
bilastine: they may enhance the serum concentration of glycoprotein IIb Inhibitors
doxorubicin: they may enhance the serum concentration of glycoprotein Inhibitors
pazopanib: they may enhance the serum concentration of glycoprotein Inhibitors
pimozide: they may enhance the serum concentration of glycoprotein IIa Inhibitors
topotecan: they may enhance the serum concentration of glycoprotein Inhibitors
vincristine: they may enhance the serum concentration of glycoprotein Inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the anticoagulant effect of thrombolytic agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
choline magnesium trisalicylate
may enhance the adverse effect of salicylates
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
choline magnesium trisalicylate
may increase the risk of adverse effects
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
tirofiban may decrease the excretion rate of ioxilan, potentially resulting in a higher serum level
when both drugs are combined, there may be an increased effect of other antiplatelet agents
may enhance the toxicity of the other through anti coagulation
may increase the antiplatelet effect of antiplatelet agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may increase the antiplatelet effect of antiplatelet agents
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increased antiplatelet effect when combined with Antiplatelet agents
it increases the toxicity of antiplatelet agents
choline magnesium trisalicylate
antiplatelet agents increase the toxicity of salicylates
other antiplatelet agents increase the toxicity of ibritumomab tiuxetan
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may increase the anti-coagulant effect of Anti-coagulants
may increase the anticoagulant effect of Anticoagulants
may enhance the effects by pharmacodynamic synergism when combined with tirofiban
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
Vitamin B12: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiplatelet agents
dasabuvir: they may increase the anticoagulant effect antiplatelet agents
tipranavir: they may increase the antiplatelet effect of antiplatelet properties
aliskiren: they may enhance the serum concentration of glycoprotein Inhibitors
celiprolol: they may enhance the serum concentration of glycoprotein Inhibitors
everolimus: they may enhance the serum concentration of glycoprotein Inhibitors
ranolazine: they may enhance the serum concentration of glycoprotein Inhibitors
romidepsin: they may enhance the serum concentration of glycoprotein Inhibitors
silodosin: they may enhance the serum concentration of glycoprotein IIa Inhibitors
tegaserod: they may enhance the serum concentration of glycoprotein Inhibitors
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
tipranavir: they may enhance the serum concentration of glycoprotein IIa Inhibitors
ritonavir: they may enhance the serum concentration of glycoprotein IIB Inhibitors
apixaban: it may increase the anticoagulant effect of agents with Antiplatelet Properties
may intensify the negative/harmful impact of caplacizumab
>10%:Â
Minor bleeding Â
1-10%:Â
Pelvic pain Â
Coronary artery dissection Â
Bradycardia Â
Dizziness Â
Lower extremity pain Â
Edema Â
Sweating Â
Major bleeding Â
ThrombocytopeniaÂ
Tirofiban is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
The drug is safe during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of the drug in breast milk.Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: tirofibanÂ
Pronounced: tye-roe-fye-banÂ
Why do we use oseltamivir?Â
Tirofiban belongs to the category of antiplatelet agents. It is used to treat Non-ST Elevation Acute Coronary Syndrome.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
